In the context of Alzheimer’s disease, O-GlcNAcylation may be beneficial because pharmacological inhibition of OGA increases tau O-GlcNAcylation, decreases tau phosphorylation, and decreases neurodegenerative phenotypes [19–24]. Here, MAPT is linked to Alzheimer disease.